chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Felt dizzy; Stomach wasn't feeling right; Face was tingling; Mild to moderate numbness around forehead; Mild to moderate numbness around mouth; A spontaneous report was received from a consumer concerning herself, a 34 year old, female patient, who developed dizziness, abdominal discomfort, tingling face and mild to moderate numbness around the forehead and mouth.   The patient's medical history was not provided. There were no relevant concomitant products reported.   On 30-Dec-2020, approximately 15 minutes prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 (Lot unknown) intramuscularly in the left deltoid arm for prophylaxis of COVID-19 infection.    On that same day, the patient was monitored for approximately 15 minutes after receiving mRNA-1273, she began to feel dizzy and her stomach was not "feeling right".  After 2 hours had passed, her face was tingling and she experienced mild to moderate numbness around the forehead and mouth. She reported she was continuing to monitor symptoms at the time of this report.   Treatment information was not provided.   Action taken with mRNA-1273 in response to the events was not provided.   The outcomes of the events were not reported.; Reporter's Comments: This case concerns a 34-year-old, female patient. The patient's medical history was not provided. The patient experienced an unexpected event of dizziness, abdominal discomfort, paraesthesia, hypoaesthesia of forehead and oral hypoaesthesia. The event of dizziness and abdominal discomfort occurred after 15 minutes and the event of paraesthesia, hypoaesthesia of head and oral hypoaesthesia occurred after 2 hours of the first dose of mRNA-1273. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
about 5hr p/vax child started to cry continuously requiring an ER visit;no fever;no sz;no vomiting;no local rxn;
Patient came in to receive Pneumonia vaccine. Pharmacist accidently gave the Flu vaccine which the patient had already received 1.5 months back
Headache, Fever & CoughWheeze Narrative: Employee woke up around 12:00am with H.A. fever, body aches, and congestion and cough. She stated she felt like she was run over by a truck. She feels very tired, worn out.
Patient was supposed to receive KINRIX, but received a 3rd HEP A in error.
Chills, extreme fatigue for approximately 8 hours  24 hours post vaccine, experiencing severe shortness of breath and fast heart beat for approximately 36 hours and continuing
Pt recvd vax & c/o achiness & fever, the next day exp bilateral cheek rash & generalized itching was seen by MD who ordered DPH; 14APR93 pt awakened w/feet, ankles & hands puffy & stated had a t101 during noc; was seen in ER:
Chills, sweating, headache, right arm red and painful, antibiotics given orally for home, injectable antibiotic given in office.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 49-year-old male patient received BNT162b2 (BNT162B2), on 20Oct2021 as dose 3 (booster), single (Lot number: EW0178) at the age of 49 years for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ATORVASTATIN; LIPITOR, start date: 20Apr2022, stop date: 21Apr2022; IBUPROFEN, start date: 20Apr2022, stop date: 25Apr2022; ROBITUSSIN DM, start date: 20Apr2022, stop date: 25Apr2022. Vaccination history included: Covid-19 vaccine (Dose 1, Primary Immunization series complete but unknown manufacturer), for COVID-19 Immunization; Covid-19 vaccine (Dose 2, Primary Immunization series complete but unknown manufacturer), for COVID-19 Immunization. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of covid-19, drug ineffective.  Clinical course: adverse event Positive with symptoms 5 days after finishing course of Paxlovid. The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously received a COVID-19 Vaccine.
Initial itching and rash at injection site, very similar to mosquito bite in a sensitive skin person. Skin was raised in about an inch circle around the injection site, lump moved with the skin and was very uncomfortable to touch. The itching subsided over a couple of days. The rash spread and there is still level 7 pain to the touch at the injection site nearly 4 weeks later.
FluMist received on Saturday. No illness at time; no CHP. Noticed red eyes (both) about an hour after getting the nasal mist; slightly pink then whites turned quite red later in day. No fever, itching, drainage, headache, sore throat, etc. Not rubbing or c/o pain. No routine medication. Was taking Claritin in past (hadn't taken for a couple days before). No med allergies or food allergies. Redness finally went away last night (Monday); "Eyes look tired" but this morning eyes appear  back to normal. Family has been healthy: No illness. Informed mother that I would report this to VAERS but that she should be able to get flu vaccine next year OK.
First dose after vaccine was open in refrigerator over 12 hour expiration time; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (First dose after vaccine was open in refrigerator over 12 hour expiration time) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 005C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 14-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (First dose after vaccine was open in refrigerator over 12 hour expiration time). On 14-May-2021, EXPIRED PRODUCT ADMINISTERED (First dose after vaccine was open in refrigerator over 12 hour expiration time) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.
The Patient is a 21 year old male. Patient complains of 2 additional smallpox vaccination blisters that occurred after initial vaccination. Patient states vomiting the day prior and feeling of generalized hot flashes, nausea. Patient denies difficulty breathing. Patient states he was covering the site adequately and as instructed. Patient states moderate itching. Patient vaccination date was 09JUN2015. Patient blisters located on left arm with two being on the deltoid and one additional in the antecubital space.
Bells Palsey - right side. Has had 3 episodes of left bells palsey in the past.
Patient had an episode where he started stumbling, feeling diaphoretic, with diffuse muscle cramping 100 m from finishing a 5K race. He reports a sore throat, headache, and some dyspnea. He reports no adverse reaction to the first COVID vaccine.  The patient had great symptomatic improvement with hydration. Patient was recommended to follow up with PCP and cardiology.
Infection at injection site, swelling on arm at site, spread down arm. Had temp for several days (had antibiotics Cipro).
Immediately upon completion of vaccination, pt lost consciousness for approximately 30 seconds, followed by vomiting, lethargy, low BP, sweating. This continued for about 20 minutes.
Pt recv'd on 7/19/11 around 4pm. After getting the vaccine her arm became very sore. About 2 weeks later she states she became very weak, & nauseous. She also had issues using her right & left leg right side of her face and teeth on right side began to be very painful, teeth eventually become numb. She also experienced extreme constipation. She developed a huge rash that covered her whole right arm, which was very painful & burning. Also experienced extreme shooting pains in both hands.
Hives arms legs & torso/ I had a reaction of hives on my arms and legs; Received the first vaccine and broke out in hives within two hours of the shot; This is a spontaneous report from a contactable consumer. This 56-year-old non-pregnant female consumer (patient) reported that she received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EP7533) via an unspecified route of administration on 01Apr2021 at 05:30 PM (at 56-year-old) on left arm, as dose 1, single for COVID-19 immunization. The patient had history of allergies to medications, food, or other products. The patient's concomitant medications were not reported. The patient was not diagnosed with COVID-19 prior to vaccination and was not tested for covid-19 since the vaccination. No other vaccines were received within 4 weeks prior to the COVID vaccine and no other medications were received within 2 weeks of vaccination. On 01Apr2021, within two hours of the shot the patient experienced hives arms legs & torso/ had a reaction of hives on my arms and legs. The patient received treatment with Benadryl. The patient was recovering.  No follow-up attempts were needed. No further information was expected.
E evaluation states vaccines have been administered to multiple patients. Customer has a list of patients but states it would take too long to read each patient name. States 39 patients total received vaccines.; No additional AE details; This spontaneous report has been received from a medical assistant, concerning a 1-years-old male patient. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, and concomitant medications were not provided.  On 22-APR-2022, the patient was administered vaccine varicella virus vaccine live (oka/merck) (VARIVAX) first dose, subcutaneously (valid lot number U025790 [expiration date 19-AUG-2023]) for prophylaxis, after a temperature excursion of -14 degrees Celsius (C) up to -10 degrees C for 3 hours (h), 0 minutes (min) and 0 seconds (sec); -10 degrees C up to 8 degrees C for 1 h, 30 min, 0 sec. The time frame of 3 h, 0 min, 0 sec; 1 h, 30, min 0 sec (product storage error) and a device component malfunction was reported (dose, vaccination scheme frequency, and anatomical location of vaccination were not provided). No previous temperature excursion was reported.  No additional adverse events (AE) were reported.  This is one of several reports received from the same reporter.  As recorded by data digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2204USA009330: US-009507513-2205USA008004: US-009507513-2205USA007821: US-009507513-2205USA007852:
Patient developed chest discomfort on 4/1/21. Troponin peak was 3.030 and EKG showed sinus bradycardia, ST elevation, consider early repolarization. Pt underwent coronary angiogram which showed angiographically normal coronaries. Patient had echocardiogram which showed normal LV and RV systolic function, no pericardial effusion. Patient underwent cardiac MRI which showed LVEF 61%, RVEF 53%, and subepicardial delayed hyperenhancement in the basal and mid infero-lateral walls of LV. This finding was consistent with acute myocarditis. Patient was discharged home with a cardiac event monitor. No medications were prescribed.
CUSTOMER COMPLAINED OF HOT FLASHES, DIZZINESS, "DID NOT FEEL WELL". SHE WAS GIVEN A VACCINATION WITH THIMEROSAL AND WAS WARNED OF THIS BEFORE ADMININSTRATION.
This case was reported by a pharmacist via call center representative and described the occurrence of pain in a female patient who received FLUARIX QUADRIVALENT. Concomitant products included FLUARIX QUADRIVALENT. On 30th August 2017, the patient received the 2nd dose of FLUARIX QUADRIVALENT (intramuscular) .5 ml. On 30th August 2017, less than a day after receiving FLUARIX QUADRIVALENT, the patient experienced pain, accidental overdose and wrong vaccine administered. On an unknown date, the outcome of the pain, accidental overdose and wrong vaccine administered were unknown. The reporter considered the pain to be possibly related to FLUARIX QUADRIVALENT. Additional details were reported as follows: The reporting pharmacist was the patient. The age at vaccination was not reported. The patient said that her pharmacist partner accidentally gave her two doses of FLUARIX QUADRIVALENT and was supposed to give one FLUARIX and one pneumococcal vaccination, which led to wrong vaccine administered and accidental overdose.
Starting almost 24 hrs after 2nd dose, developed a rash at vaccine location on left arm that grew larger circling the shot location, spread to left side of neck behind ears and red burning heat rash almost to the front of my neck.  3 days later the shot location is still quite warm while the rest of my arm and body are cold.
COVID-19 positive; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (COVID-19 positive) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Sep-2021, the patient experienced SARS-COV-2 TEST POSITIVE (COVID-19 positive). At the time of the report, SARS-COV-2 TEST POSITIVE (COVID-19 positive) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No patient treatment and concomitant medication were provided. Patient past medication history was not given. On 03-Sep-2021 she found out by rapid test she was COVID-19 positive. She was due for her second shot on 21-Sept-2021.
This case was reported by a healthcare professional and described the occurrence of left arm pruritus in a 59-year-old male subject who was vaccinated with BOOSTRIX (GlaxoSmithKline). Concurrent medical conditions included aspirin allergy and asthma. Concurrent medications included unknown blood pressure medication and unknown given for hypercholesterolemia. On 25 January 2012 at 15:45 the subject received a dose of BOOSTRIX (.5 ml, unknown route, left deltoid). On 25 January 2011, same day after vaccination with BOOSTRIX, the subject experienced l arm pruritus and ear pruritus. It was reported that the subject experienced itching on the left arm and itching on the left ear. The subject was treated with BENADRYL. At the time of reporting the itching on the left arm resolved and the outcome of the itching on the left ear was unspecified. Follow-up information was received on 10 February 2012. It was reported that the events of left arm pruritus and ear pruritus began on the day of vaccination with BOOSTRIX, 25 January 2012, and resolved the same day. There was no history of tobacco use.
our last booster was about 6 months ago, but we both had covid in September; our last booster was about 6 months ago, but we both had covid in September; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Sep2022, outcome "unknown" and all described as "our last booster was about 6 months ago, but we both had covid in September".   Clinical course: Caller was a consumer asking about the Pfizer Covid19 vaccine, explained our last booster was about 6 months ago, but they both had covid in September. They both were high-risk. Agent: E-transmit, AE for contracting covid after receiving all booster doses of vaccine. Caller stated she thought they probably had the Omicron variant of the virus. Product: Comirnaty, Pfizer-BioNTech COVID-19 Vaccine [Monovalent] and/or Bivalent Dose/Dosage Form: Gray cap, Original/Omicron BA.4/BA.5 (Bivalent), more than equal to 12 years - 15/15 mcg per dos.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201232922 Same reporter/drug/event, different Patient;
8bdays after recieved the vaccine, a red bump, that felt like a bug bite, showed up.  Bump itches,  and has began to spread out. It is warm/hot to touch. Area of ridged, as a bug bite would be, but is now about the size of my palm.
This spontaneous report was received from a 25 year old female patient referring to herself. The patient had no medical history. No drug reactions/allergies. The patient had given birth to her child on 24-JUN-2014 at a hospital. Prior to her discharge on 27-JUN-2014, the patient was vaccinated with PNEUMOVAX 23 0.5 ml in the right arm. No concomitant medications. On the same day about 3 hours later after getting the vaccination the patient experienced "severe pain" in her right shoulder and she was not able to move the shoulder either. The patient reported that the pain was severe enough where she ended up going back to the hospital emergency room (ER) later that evening due to the event but was not admitted to the hospital. The patient was told at the hospital that she was having an allergic reaction to the PNEUMOVAX 23 and she needed to follow up with her doctor. The patient reported that since that time, she has had an MRI, cortisone shots and physical therapy all to help her right shoulder because she couldn't move her shoulder for an unspecified duration. Patient stated she now was able to move her shoulder, however her shoulder would still hurt. The patient also mentioned that right after getting the PNEUMOVAX 23, she had also lost her voice for a short while. Action taken with PNEUMOVAX 23 was not applicable. The patient had not recovered from hypersensitivity, musculoskeletal pain and aphonia. The event hypersensitivity was considered to be related to PNEUMOVAX 23. Causality assessment between the events musculoskeletal pain and aphonia and PNEUMOVAX 23 was not reported. Upon internal review the events aphonia and hypersensitivity were considered serious as medically significant. Additional information has been requested.
As soon as I received the shot and went into the waiting area, I experienced a tingling sensation down my right arm where the injection was administered. Throughout the 15 minutes the sensation began to radiate throughout my body and extremities. I waited about 20 minutes before deciding to leave the facility and proceed with my afternoon.  Once I got home, I experienced chills, which I read on the pamphlet was an expected side effect. Both hands and feet were cold and I put on additional layers and lied on the couch and rested. During that time I began to notice the tingling sensation/paresthesia predominantly in the injected (right) arm, but also sporadically in other parts of my body including thigh (front/back), left arm, elbow, back, torso, neck, head, wrists, buttocks, etc. This sensation continued as I prepared for bed and continues as of this writing.  It's difficult to say whether the sensation is getting better or worse, but it is consistent best described as someone pricking you every so often.
no adverse effect; the patient received the first dose of GARDASIL 9 a year ago on an unspecified date/ the patient received the second dose of GARDASIL 9 on 5/23/2019; This spontaneous report as received from a nurse refers to a 22-year-old patient. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  In approximately May 2018 (reported as a year ago), the patient was vaccinated with a first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (strength, dose, route of administration, lot # and expiration date were not reported) for prophylaxis. On 23-MAY-2019, the patient was vaccinated with a second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # 1602281 has been verified to be a valid lot number, expiration date reported as 02-JUL-2021, but upon internal validation established as 21-JUL-2021 (strength, dose and route of administration were not reported) for prophylaxis.  On 23-MAY-2019, the patient experienced inappropriate schedule of product administration. There was no adverse effect reported.
Patient called today on 5/25/21 and said she is feeling tired and unable to walk
Received TDAP and MCV4 in left deltoid and HPV 9 in right deltoid. On 8-9-16. Morning of 8-10-16 noted redness and swelling small (left deltoid). Increased in size. Office visit 8-12-16. Left deltoid had an area of redness, swelling and tenderness 6 inches x 4 inches. Tx with KEFLEX and cool compresses.
Injection site reaction, had a big knot in arm, patient took BENADRYL. Reaction came 1 day after injection.
Urinating more; This spontaneous case was reported by a consumer and describes the occurrence of POLLAKIURIA (Urinating more) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, the patient experienced POLLAKIURIA (Urinating more). At the time of the report, POLLAKIURIA (Urinating more) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included were not provided.
received what RN thought was 2nd dose of vaccine, but it actually turned out the be booster (3rd) before 6 months after completion of primary series
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Anti-viral drug PAXLOVID was taken start from 29Jul2022 to stop date 02Aug2022 for the treatment of COVID-19. No other medication in 2 weeks. No known allergies.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.